|

Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias

RECRUITINGSponsored by IRCCS SYNLAB SDN
Actively Recruiting
SponsorIRCCS SYNLAB SDN
Started2020-03-02
Est. completion2024-02-01
Eligibility
Age1 Year – 18 Years
Healthy vol.Accepted

Summary

A transcriptomic analysis of bone marrow from B-ALL patients was performed by our research group for identifying novel protein/factor with a putative role of disease biomarker. Along with some already known B-ALL biomarkers, our analysis highlighted deregulation of some members of an emerging protein class denoted as KCTD (Potassium ChannelTetramerization Domain-containing proteins). Starting from our preliminary observations, and considering that KCTDs havenever been studied in ALL, we decided to study these proteins in B- and T-ALL affected pediatric patients, enrolled by our research group in collaboration with AORN Santobono-Pausilipon pediatric oncological hospital.Indeed, the present research program aims at opening a new scenario for the study of KCTD proteins in childhood leukemias. The final goal of the project will be to evaluate the translational relevance of selected deregulated KCTDs as novel biomarkers useful for B-ALL and T-ALL diagnostics, and patient management.

Eligibility

Age: 1 Year – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients aged 1-18 years of both sexes diagnosed with B- ALL and T-ALL;
* Patients who will have signed the informed consent

Exclusion Criteria:

* Patients who refuse to participate in the study;
* Patients who do not fall within the age range mentioned above

Conditions2

CancerChildhood Acute Lymphoblastic Leukemia

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.